Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;4(5):975-82.
doi: 10.2147/tcrm.s3172.

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Michael J Prematta  1 , Tracy Prematta, Timothy J Craig
Affiliations

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Michael J Prematta et al. Ther Clin Risk Manag. 2008 Oct.

Abstract

Background: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA.

Objective: To review the medical literature to determine if C1-INH concentrate is a safe and effective treatment for acute HAE attacks.

Methods: THE FOLLOWING KEYWORDS WERE SEARCHED IN PUBMED AND OVID: C1 esterase inhibitor, C1-inhibitor, C1 inhibitor, and hereditary angioedema treatment. English-language articles were searched from 1966 to the present to look for studies demonstrating the efficacy and the safety of C1-INH concentrate.

Results: The English-language literature search revealed several studies showing significantly improved relief of HAE symptoms with the administration of C1-INH concentrate - many studies demonstrated some improvement of symptoms within 30 minutes. Side effects have been similar to placebo, and no proven cases of viral transmission have occurred in over 20 years.

Conclusion: C1-INH concentrate appears to be a very safe and effective treatment option for HAE.

Keywords: c1 esterase inhibitor; c1 inhibitor; hereditary angioedema; hereditary angioedema treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bernstein JA. Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. Ann Allergy Asthma Immunol. 2008;100:S41–S6. - PubMed
    1. Bernstein JA, Levy R, Wasserman RL, et al. Treatment of acute abdominal and facial attacks of hereditary angioedema (HAE) with human C1 esterase inhibitor (C1-INH): results of a global, multicenter, randomized, placebo-controlled, phase I/II Study (I.M.P.A.C.T.1) [abstract] J Allergy Clin Immunol. 2008;121:795.
    1. Bork K, Barnstedt S-E. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;161:714–18. - PubMed
    1. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant) J Allergy Clin Immunol. 2007;119:1497–503. - PubMed
    1. Bork K, Meng G, Staubach P, et al. Treatment with C1-inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005;45:1774–84. - PubMed